Vedere Bio recently became a wholly-owned subsidiary of Novartis after being acquired by the pharma giant for up to $280 million--$150 million upfront, up to $130 million in milestones—in a deal designed to bolster the buyer’s expanding presence in gene therapy . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge